Argo Biopharma secures NMPA clearance for Phase II PNH trial

The therapy is examined in Phase I trial for IgA nephropathy, after NMPA approval for Phase I/IIa in June 2025. Credit: Robina Weermeijer on Unsplash.



  • The therapy